DESIGN AND EVALUATION OF PECTIN BASED MATRIX FOR TRANSDERMAL PATCHES OF MELOXICAM by MANISH KUMAR, SHARAD VISHT, PALLAVI SRIVASTAVA, G.T.KULKARNI,
JPRHC
Research Article
JPRHC                         Volume 2                                             Issue 3 244-247
DESIGN AND EVALUATION OF PECTIN BASED MATRIX FOR TRANSDERMAL PATCHES OF 
MELOXICAM
PALLAVI SRIVASTAVA, Dr. G.T.KULKARNI, MANISH KUMAR, SHARAD VISHT
For author affiliations, see end of text
This paper is available online at www.jprhc.in
ABSTRACT
Transdermal drug delivery system was developed 
using meloxicam as a model drug. Meloxicam is a 
non steroidal anti-inflammatory (NSAID) drug. 
The suitability of drug with respect to solubility, 
lower molecular weight and short half life makes 
this drug as a suitable candidate for administration 
by transdermal route. The polymer selected for the 
study is pectin. The polymer is non-toxic and 
biodegradable in nature. In the present 
investigation various concentration ratios of 
polymer were used for the fabrication of the matrix 
diffusion controlled transdermal drug delivery 
system by solvent evaporation technique. These 
transdermal drug delivery systems were 
characterized for their thickness, weight variation, 
folding endurance, swelling index, content 
uniformity, compatibility, in-vitro release and skin 
irritation studies of the drug from the polymeric 
matrix. Meloxicam was found to be compatible 
with pectin as revealed by Fourier Transform 
Infrared Spectroscopy (FTIR) studies and showed 
satisfactory physiochemical characteristics. In-vitro
release studies were carried out with modified 
Franz diffusion cell using pH 7.4 phosphate buffer 
as receptor medium and it showed controlled 
release of drug. Thus the prepared transdermal 
films can be used to achieve controlled release and 
improved bioavailability of meloxicam.
KEY WORDS: Transdermal Drug Delivery, 
Pectin, Meloxicam
INTRODUCTION
The systemic treatment of disease via transdermal 
route is not a recent innovation. But, in the last two 
decades, transdermal drug delivery has gained 
increasing interest. The delivery of drugs using 
skin as the port of entry is known as transdermal 
administration and the drug delivery systems are 
known as transdermal therapeutic systems or 
transdermal drug delivery systems or popularly 
known as transdermal patches.1 The success of this 
approach is evidenced by the fact that there are 
currently more than 35 approved transdermal drug 
delivery products for the treatment of a wide 
variety of conditions including: hypertension, 
angina, motion sicknesses, and recently 
contraception and urinary incontinence. There are 
also several products in late-stage development 
that will further expand transdermal drug delivery 
usage into new therapeutic areas, including 
Parkinson’s disease.1, 2, 3. Transdermal controlled 
drug delivery systems have been investigated & 
developed in order either to avoid hepatic first-pass 
effect improving drugs bioavailability or to 
decrease the dosing frequency required for oral 
treatment.
Meloxicam is a non-steroidal anti-inflammatory 
drug preferably used for management of pain, 
inflammation, tenderness, swelling and stiffness of 
the joints in patients of osteoarthritis, rheumatoid 
arthritis, and juvenile rheumatoid arthritis. It has 
also been used to treat signs and symptoms of 
ankylosing spondylitis, acute low back pain, and 
acute sciatica. The mean elimination half-life (t½) 
ranges from 15 hours to 20 hours. The usual oral 
dosage regimen is 7.5 mg – 15 mg once daily. 
Patient compliance in the form reduced 
administration frequency can best be achieved by 
development of matrix type transdermal patches of 
meloxicam.
MATERIALS AND METHODS
Meloxicam was obtained from Unichem Labs, India 
as a gift sample. Pectin & other chemicals including 
Dimethylformamide, Polyethylene Glycol 400, 
Menthol & Glycerin were procured from Central 
Drug House, Delhi, India. All other chemicals & 
solvents used were of analytical grade.
INVESTIGATION OF PHYSIOCHEMICAL 
COMPATIBILITY OF DRUG & POLYMER
In order to evaluate the integrity and compatibility 
of the drug with the carrier polymer in the 
polymer-drug matrix formulations, IR spectra of 
the drug and its formulations were obtained using a 
potassium bromide pellet method. For determining 
drug-polymer compatibility (100 mg) of the 
hydrogel powder was mixed with potassium 
bromide (400 mg) and was compressed in a 
hydraulic press to form a pellet at 15 tons pressure. 
The pellets were scanned in the wavelength region 
between 4000 to 400 cm-1 by FTIR 
spectrophotometer (Perkin Elmer-1000, Japan)
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PREPARATION OF MELOXICAM-
POLYMER FILMS
The transdermal films were prepared by solvent 
casting technique. The polymeric matrix was 
prepared by dissolving 6% w/v pectin in distilled 
water to which (0.1% v/v PEG) was added as 
plasticizer. The drug solution was prepared by 
dissolving (50 mg) drug in 2 mL 
dimethylformamide and shaken on a mechanical 
shaker for 30 min. to ensure complete solubilisation
of the drug. Then the drug solution was added to 
polymeric solution and mixed thoroughly by 
continuous stirring to ensure uniform distribution 
forming a homogenous mixture. To the prepared 
mixture (0.25% w/v and 0.5% w/v menthol) and 
(1% w/w and 1.5% w/w glycerin) were added as 
penetration enhancers. A measured volume of each 
of the polymeric solutions (10 mL) was poured into
petri dish and dried at room temperature. To 
prevent fast evaporation from the patches an 
inverted funnel was placed on the mould. After 
ensuring the complete evaporation of the solvent, 
patches of 2 cm diameter were cut and stored for 
further study.
Table 1 Composition of Meloxicam-Polymer Films
Ingredients  Quantity Formulation code






50 mg               50 mg            50 mg          50 mg          50 mg
6 % w/v           6 % w/v         6 % w/v         6 % w/v     6 % w/v
                        0.1 %v/v        0.1 %v/v       0.2 %v/v     0.2 %v/v
    -                  0.25 % w/v     0.5 %w/v            -                   -
    -                                                              1 % w/w      1% w/w               
FORMULATION VARIABLES
Selection of Polymer Concentration
Pectin at different concentrations was used (1% 
w/v to 10% w/v) among which 6% w/v was found 
to give better results. Film properties (surface 
properties, thickness and folding endurance) at 6% 
w/v showed better results as compared to other 
concentrations.
Selection of Plasticizer
For pectin PEG 400 at different concentrations 
(0.1% v/v to 0.5% v/v) was used as plasticizer. It 
was observed that PEG 400 at (0.1% v/v and 0.2% 
v/v) showed better film properties with good 
plasticity.
Selection of Penetration Enhancers
Various penetration enhancers were used to modify 
the release profile of the drug. Menthol at different 
concentrations (0.1% w/v to 0.5% w/v) was added 
to the films, it was observed that menthol at (0.25% 
w/v and 0.5% w/v) modified the release pattern of 
the drug. Other penetration enhancer glycerin was 
used at (1% w/w to 3% w/w), it was found that 
glycerin at (1% w/w and 1.5% w/w) concentration 
showed better results and modified the release 
pattern of the drug.
EVALUATION OF FILMS
Thickness4,5,6
The thickness of each film was measured using
digital micrometer screw gauge at three different 
positions of the film and the mean value was 
calculated.
Weight Variation4,5,6
For determining weight of films, three films of each 
formulation were taken and weighed individually 
using digital balance. The average weight was 
calculated.
Folding Endurance4,6
The folding endurance of the films was determined 
by repeatedly folding one film at same place till it 
broke. The number of times the film could be folded 
at the same place without breaking / cracking gave 
the value of folding endurance.
Swelling Studies7
A drug loaded film of 2 cm2 was weighed on a pre 
weighed cover slip. It was kept into a petri dish and 
50 mL of phosphate buffer (pH 7.4) was added. The 
films were observed for increase in weight for 10 
min. The difference in the final and initial weight 
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gives the weight increase due to absorption of 
water and swelling of films.
Surface pH8
For the determination of surface pH the patches 
were left to swell for 2 hours on the surface of agar 
plate, prepared by dissolving 2% (w/v) agar in 
warmed phosphate buffer (pH 7.4) under stirring 
and then pouring the solution into the petri dish till 
gelling at room temperature. The surface pH was 
measured by means of pH paper placed on the 
surface of swollen patches. The mean of three 
readings was recorded.
Drug content 4,9
For determining content uniformity each film of 
size 2 cm2 was cut and placed in volumetric flask 
and 10 mL of dimethylformamide was added. It was 
placed on a mechanical shaker and shaken for 3-4 
hours. Then 1 mL of the solution was transferred 
to a 10 mL volumetric flask and diluted with 
dimethylformamide up to the mark. The 
absorbance of the solutions was measured against 
corresponding blank solution using UV-Visible 
spectrophotometer at 375 nm.
In-Vitro Release Study5,9,10,11
A modified Franz diffusion cell was used to study
drug release from the transdermal films. Phosphate 
buffer pH 7.4 was used as the receptor fluid (200 
mL). Dialysis membrane hydrated over a period of 
24 hours was used as the barrier. 
Figure 1 In-vitro diffusion studies of transdermal 
film in pH 7.4 phosphate buffer
A film of 2 cm2 was placed on the donor 
compartment with the film facing dialysis 
membrane and placed in the receptor compartment. 
The cell was maintained at 37 ± 0.5 oC and 
receptor fluid was agitated at 100 rpm by a 
magnetic stirrer. Samples were withdrawn at 
hourly intervals and filtered using whattman filter 
paper and analysed for the amount of drug release 
using UV spectrophotometer at 375 nm.
Skin Irritation Studies12
The skin irritation studies were done on Guinea 
pigs. The animals were observed for any sign of 
erythema or edema for a period of 7 days and scores
as reported by Draize et al.
RESULTS AND DISCUSSION
The results obtained from different experiments of 
this work were summarized in different tables and 
graphs. All the films were soft, smooth translucent 
in texture and showed easy removal from the 
substrate. Thicknesses of all the formulations were 
in the range of (0.243 ± 0.009 mm to 0.322 ± 0.036 
mm). Formulation F4 and F5 showed increased 
thickness due to presence of glycerin. Weight of all 
the formulations was found to be uniform and 
varied from (111.6 ± 0.458 mg to 117.9 ± 0.776 
mg). Folding endurance was in the range of (73.6 ± 
1.52 to 197.6 ± 0.57)) indicating that the films 
possessed good ability to withstand breakage or 
rupture. Formulation F1 represented least value of 
folding endurance, without any plasticizer. 
Percentages swelling of various formulations were 
in the range (57% to 65%). The least percentage 
swelling was found in formulation F4 and F5 in 
comparison to F2 and F3 which can be attributed 
to presence of glycerin. The surface pH of all the 
films was found to be 7 which indicate that the pH 
was close to the pH of skin. Hence no skin irritation 
was expected. Good uniformity of drug content 
among the formulations was observed and ranged 
from (90% to 97%). The drug content analysis of 
the prepared formulations has shown that the 
process employed to prepare formulation in this 
study was capable of giving films with uniform 
drug content. Release of the drug from transdermal 
formulation is controlled by the chemical properties 
of the drug and delivery form, as well as 
physiological and physiochemical properties of the
biological membrane. Drug permeation profile from 
different formulations showed that cumulative 
percentage release of drug from the formulations 
F4 and F5 was found to be high ( 94% and 95%) as 
compared to other formulations F2 and F3 (90% 
and 92%) and F1 (86%) respectively. The drug 
release pattern was modified by incorporation of
penetration enhancers showing higher release value 
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as compared to F1 due to absence of penetration enhancer.
Table 2 Characterization of transdermal films 
Parameter F1 F2 F3 F4 F5
Avg. Thickness *
(mm)
0.243 ± 0.009 0.263 ± 0.009 0.257 ± 0.007    0.311 ± 0.015   0.322 ± 0.0367
Avg. Weight *
(mg)
   111.6 ± 
0.458
   113.2 ± 
0.655
     113.0 ± 
0.650
    116.1 ± 0.757    117.9 ± 0.776
Folding
Endurance *




300.0 ± 1.563   315.8 ± 
1.550
   330.7 ± 2.577 289.1 ± 0.953    274.8 ± 2.170
Drug Content*
(mg)
5.463 ± 0.041   5.223 ± 
0.040
    5.363 ± 0.041   5.996 ± 0.060    6.063 ± 0.041
* Average of three determinations ± S.D
Table 3 Cumulative % drug release
Time (min)
Formulation Code









































































































Figure 2 Cumulative % drug released
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CONCLUSION
Pectin based matrix for transdermal patches of 
meloxicam can be developed for effective & 
controlled management of arthritis. From the 
present study it may be concluded that transdermal 
patches of meloxicam provides the convenience of 
self application and ease of removal whenever 
required and allow the luxury of more accurate 
dosing than primary dosage forms.
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